Human papillomavirus vaccine recombinant monovalent - Japan Vaccine/MedImmune

Drug Profile

Human papillomavirus vaccine recombinant monovalent - Japan Vaccine/MedImmune

Alternative Names: HPV 11 vaccine - Japan Vaccine/MedImmune; Human papillomavirus type 11 L1 virus-like particle vaccine - Japan Vaccine/MedImmune; Human papillomavirus type 11 L1 VLP vaccine - Japan Vaccine/MedImmune; MEDI 501

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator MedImmune
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Human papillomavirus infections

Most Recent Events

  • 29 Sep 2004 Discontinued - Phase-I for Human papillomavirus infections in USA (unspecified route)
  • 27 Aug 2003 No development reported - Phase-I for Human papillomavirus infections in USA (unspecified route)
  • 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top